---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-004333"
form_type: "8-K"
ticker: "BCRX"
cik: "0000882796"
company_name: "BIOCRYST PHARMACEUTICALS INC"
filed_at: "2026-06-29T11:06:42+00:00"
generated_at: "2026-06-29T11:10:24.936308+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioCryst shuts internal discovery, closes Birmingham facility; navenibart Phase 3 enrollment complete; guidance improved

## Summary
- Board approved discontinuation of internal discovery programs and closure of Birmingham, AL facility by end 2026.
- Phase 3 ALPHA-ORBIT for navenibart (HAE) enrollment completed; top-line data expected Q3 2027.
- Resolved manufacturing delay for ORLADEYO oral pellets; product available early August 2026.
- 2026 non-GAAP operating expense guidance lowered to $420-440M from $450-470M; revenue guidance reaffirmed at $635-660M.
- BCX17725 (Netherton syndrome) Phase 1 Part 4 dosing ongoing; proof-of-concept data expected year-end 2026.

## SEC filing metadata
- accession: 0001171843-26-004333
- form_type: 8-K
- ticker: BCRX
- cik: 0000882796
- company_name: BIOCRYST PHARMACEUTICALS INC
- filed_at: 2026-06-29T11:06:42+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.05, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882796/000117184326004333/0001171843-26-004333-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882796/000117184326004333/f8k_062926.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-004333
- JSON: https://secwatch.observer/filing/0001171843-26-004333.json
- Plain text: https://secwatch.observer/filing/0001171843-26-004333.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.